RNAi Advances And Demographic Shifts Will Expand Markets

Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals, with the price target moving from about $550 to roughly $515. This reflects reduced 2026 TTR and Amvuttra revenue expectations, slightly higher discount rates, and a shift to a richer future P/E multiple, as recent Street research factors in softer near term growth alongside ongoing franchise potential.

Analyst Commentary

Street research on Alnylam Pharmaceuticals has turned more cautious on near term TTR and Amvuttra revenue expectations, yet many bullish analysts still point to meaningful long term potential for the TTR franchise and the broader pipeline. Recent notes since mid 2024 show a reset in price targets, but also continued confidence in execution, category leadership and room for sentiment to recover over time.

Several firms have revised their models following Alnylam's reduced 2026 guidance for TTR and Amvuttra. The revisions include lower revenue estimates for full year 2026 and, in some cases, trimmed peak sales assumptions. Even with these changes, a number of bullish analysts continue to see Alnylam as a key player in ATTR-CM treatment, with an eye on both current Amvuttra uptake and future assets such as nucresiran.

Recent commentary also highlights how share price volatility has outpaced the scale of the guidance change. One firm noted that a US$200m cut to 2026 TTR guidance erased over US$10b of market value. It viewed this as a clear overreaction and a sign of how sensitive sentiment is to Amvuttra's growth curve. Others see potential for guidance to be beaten if current weekly Amvuttra sales trends hold up, although that view still depends on execution in both second line and first line ATTR-CM settings.

Looking across the research, investors are being asked to weigh softer near term expectations against the possibility that Alnylam's TTR franchise retains meaningful long duration. Several analysts reference a large ATTR-CM opportunity over time, but also stress that the current launch needs to re prove itself, especially as competition intensifies and newly diagnosed patient capture becomes more important to the growth story.

Some commentary also focuses on the competitive backdrop. The failure of a key rival's Phase 3 ATTR-CM trial is seen as supportive for Amvuttra and for Alnylam's position in TTR silencers. At the same time, it introduces questions for next generation programs in patients on background tafamidis. Earlier this year, that same outcome prompted upward revisions to certain price targets and higher long range estimates for both Amvuttra and nucresiran as analysts modeled less pricing pressure and fewer competitors.

For investors following Alnylam Pharmaceuticals in August 2026, the recent research flow captures a mix of recalibrated expectations and ongoing optimism about the franchise. The key debates now center on how quickly Amvuttra demand can broaden beyond current prescribers, the resilience of first line trends, and the extent to which upcoming pipeline data can help close the gap between current valuation and Street targets.

Bullish Takeaways

• Several bullish analysts still assign price targets in the US$400 to US$455 range even after cuts. This signals that they see current valuation as discounting a lot of execution risk relative to their long term TTR and Amvuttra assumptions.
• Some research argues that the share price reaction to the US$200m 2026 TTR guidance cut, which removed over US$10b of market cap, has been excessive. That view frames recent weakness as a sentiment reset rather than a fundamental break in the Alnylam story.
• Following the failed Phase 3 ATTR-CM trial for a key competitor, bullish analysts highlight Amvuttra's current label across the full ATTR patient spectrum and see reduced competitive pressure supporting the TTR franchise and future programs such as nucresiran.
• Certain notes continue to describe Alnylam as fundamentally undervalued and point to the potential for guidance beats if weekly Amvuttra trends hold. They also emphasize a large ATTR-CM opportunity that could support long term growth if the launch re accelerates.

What’s in the News for Alnylam Pharmaceuticals

• Several law firms, including Schall, Brown & Schwartz LLP, Bragar Eagel & Squire P.C., the Law Offices of Frank R. Cruz, and Glancy Prongay Wolke & Rotter LLP, are investigating Alnylam Pharmaceuticals for potential securities fraud after the company reduced its 2026 TTR product revenue guidance by about US$200m on July 30, 2026. These probes focus on shareholder rights and the sharp share price decline that followed. Source: multiple legal firm announcements.
• Alnylam Pharmaceuticals lowered full year 2026 guidance for total net product revenues to US$4.7b to US$5.1b from prior guidance of US$4.9b to US$5.3b. The company now expects net revenues from collaborations and royalties of US$575m to US$625m compared with prior guidance of US$400m to US$500m. Source: company guidance update.
• Following the reduced 2026 sales outlook for Amvuttra and a normalization of second line demand, Alnylam reported Q2 adjusted earnings that were ahead of expectations while revenue did not meet estimates. The Law Offices of Frank R. Cruz initiated a separate federal securities fraud investigation tied to the share price reaction. Source: recent earnings and legal filings.
• Alnylam advanced its neuroscience pipeline with mivelsiran, starting a Phase 2 APPlauDS study in Down syndrome associated Alzheimer’s disease and completing enrollment in the Phase 2 cAPPricorn 1 trial in cerebral amyloid angiopathy. Phase 1 data in early onset Alzheimer’s disease showed robust and durable reductions in CSF sAPPß and Aß42 with no ARIA signal and no serious or severe adverse events attributed to the drug. Source: clinical program update.
• The company expanded a partnership with Komodo Health to roll out the Marmot analytics AI platform across Alnylam’s enterprise functions and also entered a collaboration with Inceptive Nucleics valued at up to US$2b, including US$30m upfront. The Inceptive alliance aims to apply generative AI models to Alnylam’s RNAi discovery work as part of its Alnylam 2030 pipeline goals. Source: partnership announcements.

Valuation Changes for Alnylam Pharmaceuticals

• Fair Value Estimate has moved from about $550 to roughly $515, which marks a modest reduction in the modeled upside for Alnylam Pharmaceuticals.
• Discount Rate has risen slightly from 7.23% to about 7.57%, pointing to a somewhat higher required return in updated models.
• Revenue Growth has been trimmed from roughly 40.70% to about 31.37%, indicating more cautious assumptions for future dollar revenue expansion.
• Net Profit Margin has been lowered from about 30.04% to roughly 26.84%, reflecting a softer expected earnings contribution from each dollar of sales.
• Future P/E has moved higher from roughly 26.65x to about 31.13x, suggesting that current models apply a richer earnings multiple to Alnylam Pharmaceuticals despite the reset to growth expectations.